Vir Biotechnology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting condensed consolidated financial statements for the third quarter and nine months ended September 30, 2026.

Key Highlights

  • Total assets of $1,111,855 thousand as of September 30, 2026, up from $1,002,823 thousand as of December 31, 2025, according to the filing.
  • Cash and cash equivalents were $218,866 thousand as of September 30, 2026, compared with $232,185 thousand as of December 31, 2025.
  • Long-term investments increased to $442,932 thousand as of September 30, 2026 from $314,575 thousand as of December 31, 2025.
  • Total liabilities decreased to $215,819 thousand as of September 30, 2026 from $237,547 thousand as of December 31, 2025.
  • 171,270,773 shares of common stock, $0.0001 par value per share, were outstanding as of October 28, 2026.
  • Short-term investments stood at $235,769 thousand as of September 30, 2026, compared with $228,753 thousand at year-end 2025.

Vir Biotechnology Balance Sheet Position for the Quarter Ended September 30, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR), a Delaware-incorporated company headquartered at 1800 Owens Street, Suite 900, San Francisco, California 94158, filed its quarterly report covering the period ended September 30, 2026. According to the filing, the company reported total assets of $1,111,855 thousand at the close of the quarter, an increase from $1,002,823 thousand recorded as of December 31, 2025. The company is classified as a large accelerated filer under the Exchange Act.

The filing disclosed that current assets totaled $508,273 thousand as of September 30, 2026, compared with $514,080 thousand at December 31, 2025. Within current assets, cash and cash equivalents were $218,866 thousand and short-term investments were $235,769 thousand. The increase in total assets was driven in part by growth in long-term investments, which the filing reported at $442,932 thousand as of September 30, 2026, up from $314,575 thousand at year-end 2025. Restricted cash and cash equivalents, both current and noncurrent, were reported at $1,933 thousand and $6,915 thousand, respectively.

On the liabilities side, the filing reported total current liabilities of $80,659 thousand, down from $92,815 thousand at December 31, 2025, with accounts payable of $11,324 thousand and accrued and other liabilities of $9,335 thousand. Total liabilities declined to $215,819 thousand from $237,547 thousand. The filing also noted a noncurrent contingent consideration obligation of $32,980 thousand, compared with $34,100 thousand at year-end 2025. The company disclosed that as of both September 30, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding, with 10,000,000 shares authorized and 300,000,000 shares of common stock authorized.

What Was Disclosed

Vir Biotechnology's 10-Q for Q3 2026 disclosed condensed consolidated balance sheet data as of September 30, 2026 and December 31, 2025, share count as of October 28, 2026, and forward-looking statement cautionary language. The filing covers the quarterly period ended September 30, 2026.